10^th International Virology Summit

Biography

Biography: Larry Luber Martinez R

Abstract

Parvovirus B19 is a global infection that can cause serious and life threatening disorders in susceptible patient groups. [1]  Viruses of the family Parvoviridae, are among the smallest viruses described. The first pathogenic human parvovirus was discovered and named B19 from the coding of a serum sample, number 19 in panel B, that gave anomalous results during testing for hepatitis B. [2]. Parvovirus B19 genotype 1, has a worldwide distribution. Genotypes 2 and 3 tend to be found in Europe and Africa.[3]. We present the clinical and epidemiological description of cases of aplasia of the red series without affecting hematimetric indices in HIV positive patients with positive serology to Parvovirus B19 admitted to hospitalization between April 2016 to April 2017. Sixteen cases were documented, 11 men (69%) and 5 women (31%) with an average age of 40.7 and 44.4 years respectively, 5 patients (31.25%) had positive IgM levels without IgG activity documented in the same sample and 4 of these 5 patients had abandoned treatment for their HIV (80%), the average in grams per deciliter of hemoglobin and hematocrit at the time of sampling was 8.92 g / dl  and 28.6 g / dl respectively. All the patients included had IgG titles but only 6 had positive titles with a positive reference value> 11 (37.5%) and an average CD4 / ul cells count of 115 for men and 187.2 for women. Draws attention the most prevalent opportunist in the sampling is mycobacterium tuberculosis. High viremia could represent a great risk in plasma derivatives, [4-6] and all our patients required transfusions of red blood cells units (1.4 and 4.7 times, for women and men respectively). In patients with a clearly disturbed immunity, its relevant a deep molecular investigation to define real implications, epidemiology and distribution of this agent in our country